Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The histamine H3 receptor is a predominantly brain-expressed GPCR that acts both as an autoreceptor regulating its own transmitter's synthesis/release and a heteroreceptor modulating many key CNS transmitters. Its pharmacological targeting has yielded clinical therapies for sleep disorders like narcolepsy while ongoing research explores broader neuropsychiatric applications due to its central role modulating arousal states and cognition.
Primarily coupled to Gi/o proteins: Inhibits adenylate cyclase activity, reduces cAMP formation, interacts with N-type voltage-gated calcium channels to reduce calcium influx and decrease neurotransmitter release. Can activate phospholipase A2 for arachidonic acid release; may also signal through PI3K/Akt/GSK pathways. Functions as both an autoreceptor and heteroreceptor to modulate neurotransmitter release. Displays constitutive activity.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histamine Receptor H3 (H3R).